Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AskBio009 in Adults With Hemophilia B
NCT01687608Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Feb 2013
- Primary completion
- Jan 2030
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHP648 in hemophilia B (HB), sponsored by Takeda. Primary endpoints: Treatment-related adverse events and Change from baseline in clinical laboratory evaluations. Started Feb 2013; status: active, not recruiting.
02
Drugs
SHP648
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT01687608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01687608.